Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is a global leader in musculoskeletal healthcare. The company designs, manufactures, and markets orthopedic reconstructive products, including knee and hip replacements, as well as other surgical and dental products. Zimmer Biomet competes with other major players in the medical device industry, such as Stryker Corporation and Johnson & Johnson.
On November 5, 2025, Rick Wise from Stifel Nicolaus set a price target of $110 for ZBH. At that time, the stock was trading at $87.91, suggesting a potential upside of approximately 25.13%. This optimistic outlook comes despite recent challenges faced by the company, particularly in its Knees and Hips segments.
Zimmer Biomet's third-quarter earnings per share (EPS) exceeded expectations, with an adjusted EPS of $1.90, marking a 9.2% increase from the previous year. This figure surpassed the Zacks Consensus Estimate by 1.06%. However, the company's revenue growth of 9.7% to $2 billion fell short of expectations, leading to an 8.1% decline in pre-market trading.
The stock for ZBH is currently priced at $87.58, reflecting a decrease of 15.12% with a change of -$15.6. Today, the stock has fluctuated between a low of $85.84 and a high of $93.94. Over the past year, the stock reached a high of $114.72 and a low of $85.84. The company's market capitalization stands at approximately $17.35 billion.
Despite the challenges, Zimmer Biomet reaffirmed its EPS guidance but narrowed its revenue growth outlook for 2025. The trading volume for the day is 8,564,601 shares on the NYSE, indicating active investor interest. As highlighted by TheFly, the potential upside and recent performance metrics make ZBH a stock to watch.
